Journal
ANNALS OF LABORATORY MEDICINE
Volume 38, Issue 1, Pages 1-8Publisher
KOREAN SOC LABORATORY MEDICINE
DOI: 10.3343/alm.2018.38.1.1
Keywords
Liquid biopsy; Cell-free DNA; Plasma genotyping; Non-invasive biomarkers; Clinical trials
Categories
Ask authors/readers for more resources
In the past several years, interest in the clinical utility of cell-free DNA as a noninvasive cancer biomarker has grown rapidly. Success in the development of plasma genotyping assays and other liquid biopsy assays has widened the scope of cell-free DNA use in research and the clinic. Already approved by the US Food and Drug Administration in the narrow context of epidermal growth factor receptor-mutated non-small cell lung cancer, plasma genotyping assays are currently being investigated in a wide array of clinical settings and modalities. These include plasma genotyping as a tool for early diagnosis, the detection of minimal residual disease, and the evaluation of treatment response/progression. In this review, we assess the clinical landscape of plasma genotyping assays and propose strategies for their further expansion into routine clinical care.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available